Tumor heterogeneity: Causes and consequences

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1805, Issue 1, 2010, Pages 105-117

  Marusyk, Andriy ^a   Polyak, Kornelia ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Diversity; Evolution; Selection

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; IMMUNOGLOBULIN; T LYMPHOCYTE RECEPTOR;

CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL INTERACTION; CELL POPULATION; CHROMOSOME BAND; CHRONIC MYELOID LEUKEMIA; CLONE HETEROGENEITY; COMPARATIVE GENOMIC HYBRIDIZATION; DISTANT METASTASIS; DNA DAMAGE; GENE AMPLIFICATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HEREDITY; HUMAN; KARYOTYPING; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOGENE; PHENOTYPE; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GROWTH;

GENETIC HETEROGENEITY; HUMANS; NEOPLASMS;

EID: 75549083303     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2009.11.002     Document Type: Review

References (153)

1. Fidler I.J., and Hart I.R. Biological diversity in metastatic neoplasms: origins and implications. Science 217 (1982) 998-1003
2. Dick J.E. Stem cell concepts renew cancer research. Blood 112 (2008) 4793-4807
3. Nicolson G.L. Generation of phenotypic diversity and progression in metastatic tumor cells. Cancer Metastasis Rev. 3 (1984) 25-42
4. Heppner G.H. Tumor heterogeneity. Cancer Res. 44 (1984) 2259-2265
5. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., and Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 (1994) 645-648
6. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., and Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 3983-3988
7. Visvader J.E., and Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev., Cancer 8 (2008) 755-768
8. Kelly P.N., Dakic A., Adams J.M., Nutt S.L., and Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 317 (2007) 337
9. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., and Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 456 (2008) 593-598
10. Kern S.E., and Shibata D. The fuzzy math of solid tumor stem cells: a perspective. Cancer Res. 67 (2007) 8985-8988
11. Shipitsin M., Campbell L.L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., Nikolskaya T., Serebryiskaya T., Beroukhim R., Hu M., Halushka M.K., Sukumar S., Parker L.M., Anderson K.S., Harris L.N., Garber J.E., Richardson A.L., Schnitt S.J., Nikolsky Y., Gelman R.S., and Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell 11 (2007) 259-273
12. S.Y. Park, M. Gönen, F. Michor, K. Polyak, Cellular and genetic diversity in the progression of in situ to invasive breast carcinoma. J. Clin. Invest. In press (2009).
13. Hill R.P. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res. 66 (2006) 1891-1895 discussion 1890
14. Loeffler M., and Roeder I. Conceptual models to understand tissue stem cell organization. Curr. Opin. Hematol. 11 (2004) 81-87
15. Theise N.D. Perspective: stem cells react! Cell lineages as complex adaptive systems. Exp. Hematol. 32 (2004) 25-27
16. Colvin G.A., Lambert J.F., Abedi M., Dooner M.S., Demers D., Moore B.E., Greer D., Aliotta J.M., Pimentel J., Cerny J., Lum L.G., and Quesenberry P.J. Differentiation hotspots: the deterioration of hierarchy and stochasm. Blood Cells Mol. Dis. 32 (2004) 34-41
17. Roeder I., and Loeffler M. A novel dynamic model of hematopoietic stem cell organization based on the concept of within-tissue plasticity. Exp. Hematol. 30 (2002) 853-861
18. Mintz B., and Illmensee K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 72 (1975) 3585-3589
19. Park C.C., Bissell M.J., and Barcellos-Hoff M.H. The influence of the microenvironment on the malignant phenotype. Mol. Med. Today 6 (2000) 324-329
20. Gefen O., and Balaban N.Q. The importance of being persistent: heterogeneity of bacterial populations under antibiotic stress. FEMS Microbiol. Rev. 33 (2009) 704-717
21. Balaban N.Q., Merrin J., Chait R., Kowalik L., and Leibler S. Bacterial persistence as a phenotypic switch. Science 305 (2004) 1622-1625
22. Spencer S.L., Gaudet S., Albeck J.G., Burke J.M., and Sorger P.K. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459 (2009) 428-432
23. Sanz-Moreno V., Gadea G., Ahn J., Paterson H., Marra P., Pinner S., Sahai E., and Marshall C.J. Rac activation and inactivation control plasticity of tumor cell movement. Cell 135 (2008) 510-523
24. Parmigiani G., Boca S., Lin J., Kinzler K.W., Velculescu V., and Vogelstein B. Design and analysis issues in genome-wide somatic mutation studies of cancer. Genomics 93 (2009) 17-21
25. Polyak K., Haviv I., and Campbell I.G. Co-evolution of tumor cells and their microenvironment. Trends Genet. 25 (2009) 30-38
26. Maley C.C., Galipeau P.C., Finley J.C., Wongsurawat V.J., Li X., Sanchez C.A., Paulson T.G., Blount P.L., Risques R.A., Rabinovitch P.S., and Reid B.J. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38 (2006) 468-473
27. Jones P.A., and Baylin S.B. The epigenomics of cancer. Cell 128 (2007) 683-692
28. Campbell P.J., Pleasance E.D., Stephens P.J., Dicks E., Rance R., Goodhead I., Follows G.A., Green A.R., Futreal P.A., and Stratton M.R. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 13081-13086
29. Benetkiewicz M., Piotrowski A., Diaz De Stahl T., Jankowski M., Bala D., Hoffman J., Srutek E., Laskowski R., Zegarski W., and Dumanski J.P. Chromosome 22 array-CGH profiling of breast cancer delimited minimal common regions of genomic imbalances and revealed frequent intra-tumoral genetic heterogeneity. Int. J. Oncol. 29 (2006) 935-945
30. Fujii H., Marsh C., Cairns P., Sidransky D., and Gabrielson E. Genetic divergence in the clonal evolution of breast cancer. Cancer Res. 56 (1996) 1493-1497
31. Glockner S., Buurman H., Kleeberger W., Lehmann U., and Kreipe H. Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab. Invest. 82 (2002) 1419-1426
32. Shah S.P., Morin R.D., Khattra J., Prentice L., Pugh T., Burleigh A., Delaney A., Gelmon K., Guliany R., Senz J., Steidl C., Holt R.A., Jones S., Sun M., Leung G., Moore R., Severson T., Taylor G.A., Teschendorff A.E., Tse K., Turashvili G., Varhol R., Warren R.L., Watson P., Zhao Y., Caldas C., Huntsman D., Hirst M., Marra M.A., and Aparicio S. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461 (2009) 809-813
33. Teixeira M.R., Pandis N., Bardi G., Andersen J.A., and Heim S. Karyotypic comparisons of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res. 56 (1996) 855-859
34. Torres L., Ribeiro F.R., Pandis N., Andersen J.A., Heim S., and Teixeira M.R. Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res. Treat. 102 (2007) 143-155
35. Macintosh C.A., Stower M., Reid N., and Maitland N.J. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res. 58 (1998) 23-28
36. Alvarado C., Beitel L.K., Sircar K., Aprikian A., Trifiro M., and Gottlieb B. Somatic mosaicism and cancer: a micro-genetic examination into the role of the androgen receptor gene in prostate cancer. Cancer Res. 65 (2005) 8514-8518
37. Konishi N., Hiasa Y., Matsuda H., Tao M., Tsuzuki T., Hayashi I., Kitahori Y., Shiraishi T., Yatani R., Shimazaki J., et al. Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am. J. Pathol. 147 (1995) 1112-1122
38. Gonzalez-Garcia I., Sole R.V., and Costa J. Metapopulation dynamics and spatial heterogeneity in cancer. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13085-13089
39. Samowitz W.S., and Slattery M.L. Regional reproducibility of microsatellite instability in sporadic colorectal cancer. Genes Chromosomes Cancer 26 (1999) 106-114
40. Giaretti W., Monaco R., Pujic N., Rapallo A., Nigro S., and Geido E. Intratumor heterogeneity of K-ras2 mutations in colorectal adenocarcinomas: association with degree of DNA aneuploidy. Am. J. Pathol. 149 (1996) 237-245
41. Coons S.W., Johnson P.C., and Shapiro J.R. Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human glioma. Cancer Res. 55 (1995) 1569-1577
42. Mora J., Cheung N.K., and Gerald W.L. Genetic heterogeneity and clonal evolution in neuroblastoma. Br. J. Cancer 85 (2001) 182-189
43. Califano J., van der Riet P., Westra W., Nawroz H., Clayman G., Piantadosi S., Corio R., Lee D., Greenberg B., Koch W., and Sidransky D. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 56 (1996) 2488-2492
44. Sauter G., Moch H., Gasser T.C., Mihatsch M.J., and Waldman F.M. Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer. Cytometry 21 (1995) 40-46
45. Fujii H., Yoshida M., Gong Z.X., Matsumoto T., Hamano Y., Fukunaga M., Hruban R.H., Gabrielson E., and Shirai T. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res. 60 (2000) 114-120
46. Horvai A.E., Devries S., Roy R., O'Donnell R.J., and Waldman F. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod. Pathol. 22 (2009) 1477-1488
47. Pantou D., Rizou H., Tsarouha H., Pouli A., Papanastasiou K., Stamatellou M., Trangas T., Pandis N., and Bardi G. Cytogenetic manifestations of multiple myeloma heterogeneity. Genes Chromosomes Cancer 42 (2005) 44-57
48. Tomlinson I.P., Lambros M.B., and Roylance R.R. Loss of heterozygosity analysis: practically and conceptually flawed?. Genes Chromosomes Cancer 34 (2002) 349-353
49. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., and Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008) 1801-1806
50. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz Jr. L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., and Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008) 1807-1812
51. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., Shen D., Boca S.M., Barber T., Ptak J., Silliman N., Szabo S., Dezso Z., Ustyanksky V., Nikolskaya T., Nikolsky Y., Karchin R., Wilson P.A., Kaminker J.S., Zhang Z., Croshaw R., Willis J., Dawson D., Shipitsin M., Willson J.K., Sukumar S., Polyak K., Park B.H., Pethiyagoda C.L., Pant P.V., Ballinger D.G., Sparks A.B., Hartigan J., Smith D.R., Suh E., Papadopoulos N., Buckhaults P., Markowitz S.D., Parmigiani G., Kinzler K.W., Velculescu V.E., and Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007) 1108-1113
52. Siegmund K.D., Marjoram P., Woo Y.J., Tavare S., and Shibata D. Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 4828-4833
53. C.A. Janeway, Immunobiology : the immune system in health and disease / Charles A. Janeway, Jr. [et al.], 6th ed. 2005.
54. van Dongen J.J., Langerak A.W., Bruggemann M., Evans P.A., Hummel M., Lavender F.L., Delabesse E., Davi F., Schuuring E., Garcia-Sanz R., van Krieken J.H., Droese J., Gonzalez D., Bastard C., White H.E., Spaargaren M., Gonzalez M., Parreira A., Smith J.L., Morgan G.J., Kneba M., and Macintyre E.A. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17 (2003) 2257-2317
55. Mullighan C.G., Phillips L.A., Su X., Ma J., Miller C.B., Shurtleff S.A., and Downing J.R. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322 (2008) 1377-1380
56. Panzer-Grumayer E.R., Cazzaniga G., van der Velden V.H., del Giudice L., Peham M., Mann G., Eckert C., Schrauder A., Germano G., Harbott J., Basso G., Biondi A., van Dongen J.J., Gadner H., and Haas O.A. Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection. Clin. Cancer Res. 11 (2005) 7720-7727
57. Peham M., Konrad M., Harbott J., Konig M., Haas O.A., and Panzer-Grumayer E.R. Clonal variation of the immunogenotype in relapsed ETV6/RUNX1-positive acute lymphoblastic leukemia indicates subclone formation during early stages of leukemia development. Genes Chromosomes Cancer 39 (2004) 156-160
58. Zuna J., Ford A.M., Peham M., Patel N., Saha V., Eckert C., Kochling J., Panzer-Grumayer R., Trka J., and Greaves M. TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia. Clin. Cancer Res. 10 (2004) 5355-5360
59. Young R.M., Turner B.C., and Refaeli Y. B-cell receptor signaling in the genesis and maintenance of B-cell lymphoma. Future Oncol. 4 (2008) 591-594
60. Pandis N., Jin Y., Gorunova L., Petersson C., Bardi G., Idvall I., Johansson B., Ingvar C., Mandahl N., Mitelman F., et al. Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotypic subgroups. Genes Chromosomes Cancer 12 (1995) 173-185
61. Teixeira M.R., Pandis N., Bardi G., Andersen J.A., Mitelman F., and Heim S. Clonal heterogeneity in breast cancer: karyotypic comparisons of multiple intra- and extra-tumorous samples from 3 patients. Int. J. Cancer 63 (1995) 63-68
62. Kallioniemi O.P. Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. Cytometry 9 (1988) 164-169
63. Klein C.A., Schmidt-Kittler O., Schardt J.A., Pantel K., Speicher M.R., and Riethmuller G. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4494-4499
64. Nakamura T., Kuwai T., Kitadai Y., Sasaki T., Fan D., Coombes K.R., Kim S.J., and Fidler I.J. Zonal heterogeneity for gene expression in human pancreatic carcinoma. Cancer Res. 67 (2007) 7597-7604
65. Leith J.T., Michelson S., Faulkner L.E., and Bliven S.F. Growth properties of artificial heterogeneous human colon tumors. Cancer Res. 47 (1987) 1045-1051
66. Hughes S., and Lasken R. Whole genome amplification (2005), Scion, Bloxham
67. Lage J.M., Leamon J.H., Pejovic T., Hamann S., Lacey M., Dillon D., Segraves R., Vossbrinck B., Gonzalez A., Pinkel D., Albertson D.G., Costa J., and Lizardi P.M. Whole genome analysis of genetic alterations in small DNA samples using hyperbranched strand displacement amplification and array-CGH. Genome Res. 13 (2003) 294-307
68. Fialkow P.J. Clonal origin of human tumors. Annu. Rev. Med. 30 (1979) 135-143
69. R.A. Weinberg, The biology of cancer / Robert A. Weinberg
70. Novelli M.R., Williamson J.A., Tomlinson I.P., Elia G., Hodgson S.V., Talbot I.C., Bodmer W.F., and Wright N.A. Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science 272 (1996) 1187-1190
71. Leroi A.M., Koufopanou V., and Burt A. Cancer selection. Nat. Rev., Cancer 3 (2003) 226-231
72. Gatenby R.A., and Vincent T.L. Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies. Mol. Cancer Ther. 2 (2003) 919-927
73. Sieber O.M., Tomlinson S.R., and Tomlinson I.P. Tissue, cell and stage specificity of (epi)mutations in cancers. Nat. Rev., Cancer 5 (2005) 649-655
74. M. Kimura, The neutral theory of molecular evolution / Motoo Kimura
75. Merlo L.M., Pepper J.W., Reid B.J., and Maley C.C. Cancer as an evolutionary and ecological process. Nat. Rev., Cancer 6 (2006) 924-935
76. M.A. Nowak, Evolutionary dynamics : exploring the equations of life / Martin A. Nowak 2006.
77. Priyanga A. Competitive coexistence in spatially structured environments: a synthesis. Ecol. Lett. 6 (2003) 1109-1122
78. Chesson P. Mechanisms of maintenance of species diversity. Ann. Rev. Ecolog. Syst. 31 (2000) 343-366
79. Rainey P.B., and Travisano M. Adaptive radiation in a heterogeneous environment. Nature 394 (1998) 69-72
80. Korona R., Nakatsu C.H., Forney L.J., and Lenski R.E. Evidence for multiple adaptive peaks from populations of bacteria evolving in a structured habitat. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 9037-9041
81. Gatenby R.A., and Vincent T.L. An evolutionary model of carcinogenesis. Cancer Res. 63 (2003) 6212-6220
82. Greaves M. Cancer: The Evolutionary Legacy. 1 edition (2002), Oxford University Press
83. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
84. Bissig H., Richter J., Desper R., Meier V., Schraml P., Schaffer A.A., Sauter G., Mihatsch M.J., and Moch H. Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. Am. J. Pathol. 155 (1999) 267-274
85. Cheng L., Bostwick D.G., Li G., Wang Q., Hu N., Vortmeyer A.O., and Zhuang Z. Allelic imbalance in the clonal evolution of prostate carcinoma. Cancer 85 (1999) 2017-2022
86. Kuukasjarvi T., Karhu R., Tanner M., Kahkonen M., Schaffer A., Nupponen N., Pennanen S., Kallioniemi A., Kallioniemi O.P., and Isola J. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 57 (1997) 1597-1604
87. Ramaswamy S., Ross K.N., Lander E.S., and Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33 (2003) 49-54
88. Weigelt B., Glas A.M., Wessels L.F., Witteveen A.T., Peterse J.L., and van't Veer L.J. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15901-15905
89. Weigelt B., Hu Z., He X., Livasy C., Carey L.A., Ewend M.G., Glas A.M., Perou C.M., and Van't Veer L.J. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 65 (2005) 9155-9158
90. Liu W., Laitinen S., Khan S., Vihinen M., Kowalski J., Yu G., Chen L., Ewing C.M., Eisenberger M.A., Carducci M.A., Nelson W.G., Yegnasubramanian S., Luo J., Wang Y., Xu J., Isaacs W.B., Visakorpi T., and Bova G.S. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 15 (2009) 559-565
91. Ruijter E.T., van de Kaa C.A., Schalken J.A., Debruyne F.M., and Ruiter D.J. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J. Pathol. 180 (1996) 295-299
92. Aihara M., Wheeler T.M., Ohori M., and Scardino P.T. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 43 (1994) 60-66 discussion 66-67
93. Schlimok G., Funke I., Holzmann B., Gottlinger G., Schmidt G., Hauser H., Swierkot S., Warnecke H.H., Schneider B., Koprowski H., et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 8672-8676
94. Passlick B., Izbicki J.R., Kubuschok B., Nathrath W., Thetter O., Pichlmeier U., Schweiberer L., Riethmuller G., and Pantel K. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J. Clin. Oncol. 12 (1994) 1827-1832
95. Husemann Y., Geigl J.B., Schubert F., Musiani P., Meyer M., Burghart E., Forni G., Eils R., Fehm T., Riethmuller G., and Klein C.A. Systemic spread is an early step in breast cancer. Cancer Cell 13 (2008) 58-68
96. Klein C.A., Blankenstein T.J., Schmidt-Kittler O., Petronio M., Polzer B., Stoecklein N.H., and Riethmuller G. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360 (2002) 683-689
97. Schmidt-Kittler O., Ragg T., Daskalakis A., Granzow M., Ahr A., Blankenstein T.J., Kaufmann M., Diebold J., Arnholdt H., Muller P., Bischoff J., Harich D., Schlimok G., Riethmuller G., Eils R., and Klein C.A. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 7737-7742
98. Bedenne L., Michel P., Bouche O., Milan C., Mariette C., Conroy T., Pezet D., Roullet B., Seitz J.F., Herr J.P., Paillot B., Arveux P., Bonnetain F., and Binquet C. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J. Clin. Oncol. 25 (2007) 1160-1168
99. Stoecklein N.H., Hosch S.B., Bezler M., Stern F., Hartmann C.H., Vay C., Siegmund A., Scheunemann P., Schurr P., Knoefel W.T., Verde P.E., Reichelt U., Erbersdobler A., Grau R., Ullrich A., Izbicki J.R., and Klein C.A. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 13 (2008) 441-453
100. Tutt A., and Ashworth A. Close relatives or distant cousins?. Lancet Oncol. 4 (2003) 593-594
101. Podsypanina K., Du Y.C., Jechlinger M., Beverly L.J., Hambardzumyan D., and Varmus H. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321 (2008) 1841-1844
102. Gadi V.K., and Nelson J.L. Fetal microchimerism in women with breast cancer. Cancer Res. 67 (2007) 9035-9038
103. Solakoglu O., Maierhofer C., Lahr G., Breit E., Scheunemann P., Heumos I., Pichlmeier U., Schlimok G., Oberneder R., Kollermann M.W., Kollermann J., Speicher M.R., and Pantel K. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 2246-2251
104. Gangnus R., Langer S., Breit E., Pantel K., and Speicher M.R. Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin. Cancer Res. 10 (2004) 3457-3464
105. Abbruzzese J.L., Abbruzzese M.C., Hess K.R., Raber M.N., Lenzi R., and Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J. Clin. Oncol. 12 (1994) 1272-1280
106. Klein C.A., and Holzel D. Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle 5 (2006) 1788-1798
107. Arteaga C.L., and Baselga J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?. Cancer Cell 5 (2004) 525-531
108. Nowell P.C. The clonal evolution of tumor cell populations. Science 194 (1976) 23-28
109. Michor F., Iwasa Y., and Nowak M.A. Dynamics of cancer progression. Nat. Rev., Cancer 4 (2004) 197-205
110. Deininger M., Buchdunger E., and Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005) 2640-2653
111. Hofmann W.K., Komor M., Wassmann B., Jones L.C., Gschaidmeier H., Hoelzer D., Koeffler H.P., and Ottmann O.G. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102 (2003) 659-661
112. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., Lai J.L., Philippe N., Facon T., Fenaux P., and Preudhomme C. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100 (2002) 1014-1018
113. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., Sawyers C.L., and Multiple B.-A. kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
114. Corless C.L., and Heinrich M.C. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu. Rev. Pathol. 3 (2008) 557-586
115. Edwards S.L., Brough R., Lord C.J., Natrajan R., Vatcheva R., Levine D.A., Boyd J., Reis-Filho J.S., and Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451 (2008) 1111-1115
116. Sakai W., Swisher E.M., Karlan B.Y., Agarwal M.K., Higgins J., Friedman C., Villegas E., Jacquemont C., Farrugia D.J., Couch F.J., Urban N., and Taniguchi T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451 (2008) 1116-1120
117. Pierga J.Y., Reis-Filho J.S., Cleator S.J., Dexter T., Mackay A., Simpson P., Fenwick K., Iravani M., Salter J., Hills M., Jones C., Ashworth A., Smith I.E., Powles T., and Dowsett M. Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Br. J. Cancer 96 (2007) 341-351
118. Blagosklonny M.V. Oncogenic resistance to growth-limiting conditions. Nat. Rev., Cancer 2 (2002) 221-225
119. Laconi E., Doratiotto S., and Vineis P. The microenvironments of multistage carcinogenesis. Semin. Cancer Biol. 18 (2008) 322-329
120. Thilly W.G. Have environmental mutagens caused oncomutations in people?. Nat. Genet. 34 (2003) 255-259
121. Haddow A. Cellular inhibition and the origin of cancer. Acta Unio Int Contra Cancrum (1938) 342-352
122. Marusyk A., Casás-Selves M., Henry C.J., Zaberezhnyy V., Klawitter J., Christians U., and DeGregori J. Irradiation alters selection for oncogenic mutations in hematopoietic progenitors. Cancer Res. 69 (2009) 7262-7269
123. Crespi B., and Summers K. Evolutionary biology of cancer. Trends Ecol. Evol. 20 (2005) 545-552
124. Pienta K.J., McGregor N., Axelrod R., and Axelrod D.E. Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Transl. Oncol. 1 (2008) 158-164
125. Heppner G.H. Cancer cell societies and tumor progression. Stem Cells 11 (1993) 199-203
126. Bissell M.J., and Labarge M.A. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment?. Cancer Cell 7 (2005) 17-23
127. Lowe S.W., Cepero E., and Evan G. Intrinsic tumour suppression. Nature 432 (2004) 307-315
128. Wilson A., Murphy M.J., Oskarsson T., Kaloulis K., Bettess M.D., Oser G.M., Pasche A.C., Knabenhans C., Macdonald H.R., and Trumpp A. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev. 18 (2004) 2747-2763
129. Zhang J., Grindley J.C., Yin T., Jayasinghe S., He X.C., Ross J.T., Haug J.S., Rupp D., Porter-Westpfahl K.S., Wiedemann L.M., Wu H., and Li L. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441 (2006) 518-522
130. Marusyk A., and DeGregori J. Declining cellular fitness with age promotes cancer initiation by selecting for adaptive oncogenic mutations. Biochim. Biophys. Acta 1785 (2008) 1-11
131. Bilousova G., Marusyk A., Porter C.C., Cardiff R.D., and DeGregori J. Impaired DNA replication within progenitor cell pools promotes leukemogenesis. PLoS Biol 3 (2005) e401
132. Laconi S., Pani P., Pillai S., Pasciu D., Sarma D.S., Laconi E., and growth-constrained environment drives tumor progression invivo A. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 7806-7811
133. Lensch M.W., Rathbun R.K., Olson S.B., Jones G.R., and Bagby Jr. G.C. Selective pressure as an essential force in molecular evolution of myeloid leukemic clones: a view from the window of Fanconi anemia. Leukemia 13 (1999) 1784-1789
134. Begon M., Harper J.L., and Townsnd C.R. Ecology. 3rd edition (1998), Blackwell Science
135. Nagy J.D. Competition and natural selection in a mathematical model of cancer. Bull. Math. Biol. 66 (2004) 663-687
136. Devireddy L.R., Gazin C., Zhu X., and Green M.R. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 123 (2005) 1293-1305
137. Miller B.E., Miller F.R., Wilburn D.J., and Heppner G.H. Analysis of tumour cell composition in tumours composed of paired mixtures of mammary tumour cell lines. Br. J. Cancer 56 (1987) 561-569
138. Miller B.E., Miller F.R., Wilburn D., and Heppner G.H. Dominance of a tumor subpopulation line in mixed heterogeneous mouse mammary tumors. Cancer Res. 48 (1988) 5747-5753
139. Holmgren L., O'Reilly M.S., and Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1 (1995) 149-153
140. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., and Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
141. Guba M., Cernaianu G., Koehl G., Geissler E.K., Jauch K.W., Anthuber M., Falk W., and Steinbauer M. A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Res. 61 (2001) 5575-5579
142. Czaran T.L., Hoekstra R.F., and Pagie L. Chemical warfare between microbes promotes biodiversity. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 786-790
143. Tomlinson I.P. Game-theory models of interactions between tumour cells. Eur. J. Cancer 33 (1997) 1495-1500
144. Mallepell S., Krust A., Chambon P., and Brisken C. Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 2196-2201
145. McAllister S.S., Gifford A.M., Greiner A.L., Kelleher S.P., Saelzler M.P., Ince T.A., Reinhardt F., Harris L.N., Hylander B.L., Repasky E.A., and Weinberg R.A. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 133 (2008) 994-1005
146. Tomlinson I.P., and Bodmer W.F. Modelling the consequences of interactions between tumour cells. Br. J. Cancer 75 (1997) 157-160
147. Yamamoto K., Hanada R., Kikuchi A., Ichikawa M., Aihara T., Oguma E., Moritani T., Shimanuki Y., Tanimura M., and Hayashi Y. Spontaneous regression of localized neuroblastoma detected by mass screening. J. Clin. Oncol. 16 (1998) 1265-1269
148. Gross K. Positive interactions among competitors can produce species-rich communities. Ecol. Lett. 11 (2008) 929-936
149. Axelrod R., and Hamilton W.D. The evolution of cooperation. Science 211 (1981) 1390-1396
150. Axelrod R., Axelrod D.E., and Pienta K.J. Evolution of cooperation among tumor cells. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 13474-13479
151. Lyons J.G., Lobo E., Martorana A.M., and Myerscough M.R. Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions. Clin. Exp. Metastasis 25 (2008) 665-677
152. Maley C.C., Reid B.J., and Forrest S. Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiol. Biomarkers Prev. 13 (2004) 1375-1384
153. Gatenby R.A., Silva A.S., Gillies R.J., and Frieden B.R. Adaptive therapy. Cancer Res. 69 (2009) 4894-4903